JP2011528371A5 - - Google Patents

Download PDF

Info

Publication number
JP2011528371A5
JP2011528371A5 JP2011518897A JP2011518897A JP2011528371A5 JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5 JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011518897 A JP2011518897 A JP 2011518897A JP 2011528371 A5 JP2011528371 A5 JP 2011528371A5
Authority
JP
Japan
Prior art keywords
composition
item
immunogenic
particle
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011518897A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011528371A (ja
JP5781929B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/050764 external-priority patent/WO2010009277A2/en
Publication of JP2011528371A publication Critical patent/JP2011528371A/ja
Publication of JP2011528371A5 publication Critical patent/JP2011528371A5/ja
Application granted granted Critical
Publication of JP5781929B2 publication Critical patent/JP5781929B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011518897A 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物 Expired - Fee Related JP5781929B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8094208P 2008-07-15 2008-07-15
US61/080,942 2008-07-15
PCT/US2009/050764 WO2010009277A2 (en) 2008-07-15 2009-07-15 Immunogenic amphipathic peptide compositions

Publications (3)

Publication Number Publication Date
JP2011528371A JP2011528371A (ja) 2011-11-17
JP2011528371A5 true JP2011528371A5 (https=) 2012-08-30
JP5781929B2 JP5781929B2 (ja) 2015-09-24

Family

ID=41478598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011518897A Expired - Fee Related JP5781929B2 (ja) 2008-07-15 2009-07-15 免疫原性の両親媒性ペプチド組成物

Country Status (5)

Country Link
US (1) US20110250237A1 (https=)
EP (1) EP2313085A2 (https=)
JP (1) JP5781929B2 (https=)
CA (1) CA2730737A1 (https=)
WO (1) WO2010009277A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US20100015171A1 (en) * 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
EP4218799A1 (en) 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
WO2011130379A1 (en) * 2010-04-13 2011-10-20 Novartis Ag Benzonapthyridine compositions and uses thereof
EP2590625B1 (en) 2010-07-06 2017-09-20 GlaxoSmithKline Biologicals SA Cationic oil-in-water emulsions
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2013120302A (ru) 2010-10-01 2014-11-20 Модерна Терапьютикс, Инк. Сконструированные нуклеиновые кислоты и способы их применения
WO2012065263A1 (en) * 2010-11-15 2012-05-24 Sanofi Pasteur Limited Immunogenic compositions
WO2012089231A1 (en) * 2010-12-30 2012-07-05 Okairòs Ag Paramyxovirus vaccines
WO2012129483A1 (en) 2011-03-24 2012-09-27 Novartis Ag Adjuvant nanoemulsions with phospholipids
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
DK2707385T3 (da) 2011-05-13 2017-11-20 Glaxosmithkline Biologicals Sa RSV-F-præfusionsantigener
PL3586861T3 (pl) 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
CA2840965C (en) 2011-07-06 2021-03-02 Novartis Ag Cationic oil-in-water emulsions
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RU2648950C2 (ru) 2011-10-03 2018-04-02 Модерна Терапьютикс, Инк. Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение
CN104114572A (zh) 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243948A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
US9512456B2 (en) 2012-08-14 2016-12-06 Modernatx, Inc. Enzymes and polymerases for the synthesis of RNA
PE20150646A1 (es) 2012-08-16 2015-05-21 Ipierian Inc Metodos de tratamiento de una tauopatia
EA201590683A1 (ru) 2012-11-20 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Тримеры rsv f, предшествующие слиянию
US20140141037A1 (en) * 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
WO2014081507A1 (en) 2012-11-26 2014-05-30 Moderna Therapeutics, Inc. Terminally modified rna
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
JP2016517440A (ja) * 2013-03-15 2016-06-16 ブイエルピー バイオテック，インコーポレイテッド パリビズマブエピトープベースのウイルス様粒子
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015122922A1 (en) 2014-02-14 2015-08-20 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
SG10201912038TA (en) 2014-04-23 2020-02-27 Modernatx Inc Nucleic acid vaccines
EP2974739A1 (en) 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
CN106659777A (zh) 2014-06-13 2017-05-10 葛兰素史密丝克莱恩生物有限公司 免疫原性组合产品
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
CN106999444B (zh) 2014-10-03 2023-12-12 安吉尼科分子传输公司 完整的细菌衍生的囊泡对小分子化合物的增强装载
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
JP2018500389A (ja) * 2014-12-10 2018-01-11 華西亞生醫有限公司 効率的な抗体産生のための免疫化に使用される新規なタンパク質構造
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
AU2016336344A1 (en) 2015-10-05 2018-04-19 Modernatx, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2020028319A1 (en) * 2018-07-30 2020-02-06 Sinica, Academia Therapeutic nanoparticles by coacervate complexation and their use for treating bacteria
KR102184153B1 (ko) * 2019-02-25 2020-11-30 부산대학교 산학협력단 고분자 지지체 기반의 인플루엔자 바이러스 유사 구조체 및 이의 제조방법
US20220183277A1 (en) * 2019-03-22 2022-06-16 Kansas State University Research Foundation Lipid encasing amphipathic peptides
US12233177B2 (en) 2019-09-16 2025-02-25 Amgen Inc. Method for external sterilization of drug delivery device
IL302397A (en) * 2020-10-28 2023-06-01 Sanofi Pasteur Liposomes containing a TLR4 agonist, their preparation and uses
WO2022103927A1 (en) * 2020-11-12 2022-05-19 Shape Biopharmaceuticals Inc. Immunogenic compositions for coronaviruses
WO2023018876A2 (en) * 2021-08-11 2023-02-16 The Regents Of The University Of California Barrier function preserving peptides for membranes
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0749376B2 (ja) * 1988-12-16 1995-05-31 アルバニー メディカル カレジ 免疫原性組成物および医薬組成物
ATE273320T1 (de) * 1996-04-11 2004-08-15 Univ British Columbia Fusogene liposomen
US7208314B2 (en) * 2002-02-26 2007-04-24 Mirus Bio Corporation Compositions and methods for drug delivery using pH sensitive molecules
EP2314285B2 (en) * 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
EP1677763A1 (en) * 2003-10-01 2006-07-12 Children's Hospital & Research Center at Oakland Lipophilic drug delivery vehicle and methods of use thereof
US8252338B2 (en) * 2005-11-10 2012-08-28 The Regents Of The University Of California Synthetic LDL as targeted drug delivery vehicle

Similar Documents

Publication Publication Date Title
JP2011528371A5 (https=)
JP4294584B2 (ja) 核酸ワクチン接種の免疫応答を高めるための方法
DK2729127T3 (en) METHODS FOR LIPOSOMES PREPARATION
US20170307612A1 (en) Kit for detecting virus
JP2016504312A5 (https=)
Carmona-Ribeiro et al. Cationic nanostructures for vaccines design
EA017887B1 (ru) Полимерные мультиэпитопные вакцины против гриппа
JP6119030B2 (ja) インフルエンザを治療するための組成物及び方法
JP4634997B2 (ja) ウィロソーム様粒子
TW201427686A (zh) 改良之疫苗組成物及使用方法
JP7409594B2 (ja) 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用
MX2011002267A (es) Vacuna.
JP7103726B2 (ja) 医薬組成物、脂質ベシクル粒子の分粒を含む調製のための方法、及びそれらの使用
WO2007132790A1 (ja) 細菌菌体成分を含む脂質膜を有するリポソーム
CN103002908B (zh) 粘膜疫苗
Jalilian et al. Properties and prospects of adjuvants in influenza vaccination-messy precipitates or blessed opportunities?
US20240366747A1 (en) Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JPH08506592A (ja) ３−ｏ−脱アシル化モノホスホリル脂質Ａ含有のインフルエンザワクチン組成物
US10426828B2 (en) Compositions of multimeric-multiepitope influenza polypeptides and their production
TW201217000A (en) Vaccine compositions based on sticholysin encapsulated into liposomes
CN103282049B (zh) 免疫原性组合物
KR20110061611A (ko) 백신 보조제 조합
US12006350B2 (en) Triblock peptide amphiphiles, micelles and methods of use
Mendoza‐Ramírez et al. Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases
Aston-Deaville Development of improved bioprocessing methods for the manufacture of a vaccine against meningococcal meningitis